<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>the akampioneer &#187; Company News</title>
	<atom:link href="http://akampioneer.com/category/company-news/feed" rel="self" type="application/rss+xml" />
	<link>http://akampioneer.com</link>
	<description></description>
	<lastBuildDate>Mon, 14 May 2012 08:00:40 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.1</generator>
		<item>
		<title>Company News: Curetis AG Achieves CE-Marking for Unyvero™ Solution and Initiates Commercialization</title>
		<link>http://akampioneer.com/company-news/company-news-curetis-ag-achieves-ce-marking-for-unyvero%e2%84%a2-solution-and-initiates-commercialization.html</link>
		<comments>http://akampioneer.com/company-news/company-news-curetis-ag-achieves-ce-marking-for-unyvero%e2%84%a2-solution-and-initiates-commercialization.html#comments</comments>
		<pubDate>Mon, 14 May 2012 08:00:40 +0000</pubDate>
		<dc:creator>akampion</dc:creator>
				<category><![CDATA[Company News]]></category>
		<category><![CDATA[CE-marking]]></category>
		<category><![CDATA[commercialization]]></category>
		<category><![CDATA[Curetis AG]]></category>
		<category><![CDATA[ECCMID]]></category>
		<category><![CDATA[in-vitro]]></category>
		<category><![CDATA[infectious diseases]]></category>
		<category><![CDATA[molecular diagnostics]]></category>
		<category><![CDATA[pneumonia diagnostics]]></category>
		<category><![CDATA[Unyvero™]]></category>
		<category><![CDATA[Unyvero™ P50 Pneumonia Cartridge]]></category>

		<guid isPermaLink="false">http://akampioneer.com/?p=2717</guid>
		<description><![CDATA[- Successful completion of performance evaluation study; CE Mark for Unyvero™ instrument system and pneumonia application - Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious diseases, today announced that the company has achieved the CE marking for its Unyvero™ suite of instruments and the [...]]]></description>
		<wfw:commentRss>http://akampioneer.com/company-news/company-news-curetis-ag-achieves-ce-marking-for-unyvero%e2%84%a2-solution-and-initiates-commercialization.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Company News: Jean-Paul Prieels joins VAXIMM’s Board of Directors</title>
		<link>http://akampioneer.com/company-news/company-news-jean-paul-prieels-joins-vaximm%e2%80%99s-board-of-directors.html</link>
		<comments>http://akampioneer.com/company-news/company-news-jean-paul-prieels-joins-vaximm%e2%80%99s-board-of-directors.html#comments</comments>
		<pubDate>Thu, 03 May 2012 08:11:52 +0000</pubDate>
		<dc:creator>akampion</dc:creator>
				<category><![CDATA[Company News]]></category>
		<category><![CDATA[Basel]]></category>
		<category><![CDATA[BB Biotech Ventures]]></category>
		<category><![CDATA[BioMedPartners]]></category>
		<category><![CDATA[cancer vaccines]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[Jean-Paul Prieels]]></category>
		<category><![CDATA[joint venture]]></category>
		<category><![CDATA[Mannheim]]></category>
		<category><![CDATA[Merck KGaA]]></category>
		<category><![CDATA[Merck Serono Ventures]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[pancreatic cancer]]></category>
		<category><![CDATA[spin-off]]></category>
		<category><![CDATA[Sunstone Capital]]></category>
		<category><![CDATA[VAXIMM AG]]></category>
		<category><![CDATA[VXM01]]></category>

		<guid isPermaLink="false">http://akampioneer.com/?p=2698</guid>
		<description><![CDATA[VAXIMM AG, a Swiss-German biotech spin-off from Merck KGaA focusing on cancer vaccines, announced today the appointment of Jean-Paul Prieels as a new member of its Board of Directors. Dr. Prieels is a renowned industry expert in the vaccine field. He held various executive positions at GlaxoSmithKline, where he headed the vaccine research and development [...]]]></description>
		<wfw:commentRss>http://akampioneer.com/company-news/company-news-jean-paul-prieels-joins-vaximm%e2%80%99s-board-of-directors.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Company News: Nanobiotix and Thomas Jefferson University Start Research Collaboration</title>
		<link>http://akampioneer.com/company-news/company-news-nanobiotix-and-thomas-jefferson-university-start-research-collaboration.html</link>
		<comments>http://akampioneer.com/company-news/company-news-nanobiotix-and-thomas-jefferson-university-start-research-collaboration.html#comments</comments>
		<pubDate>Wed, 02 May 2012 15:55:33 +0000</pubDate>
		<dc:creator>akampion</dc:creator>
				<category><![CDATA[Company News]]></category>
		<category><![CDATA[2-year preclinical research program]]></category>
		<category><![CDATA[Bo Lu]]></category>
		<category><![CDATA[collaboration]]></category>
		<category><![CDATA[Laurent Levy]]></category>
		<category><![CDATA[Nanobiotix]]></category>
		<category><![CDATA[NanoXray]]></category>
		<category><![CDATA[NBTXR3]]></category>
		<category><![CDATA[Thomas Jefferson University]]></category>

		<guid isPermaLink="false">http://akampioneer.com/?p=2690</guid>
		<description><![CDATA[- Nanomedicine and Medical Education leaders are joining their forces in the United States to accelerate the development of NanoXray - Nanobiotix, a company developing novel cancer nanotherapeutics and Thomas Jefferson University, one of Philadelphia&#8217;s premier medical and health sciences universities, today announced that they have entered into a research collaboration to accelerate the development [...]]]></description>
		<wfw:commentRss>http://akampioneer.com/company-news/company-news-nanobiotix-and-thomas-jefferson-university-start-research-collaboration.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Company News: Probiodrug AG, Collaborators Explain Interplay of Key Suspects in Alzheimer’s Disease</title>
		<link>http://akampioneer.com/company-news/company-news-probiodrug-ag-collaborators-explain-interplay-of-key-suspects-in-alzheimer%e2%80%99s-disease.html</link>
		<comments>http://akampioneer.com/company-news/company-news-probiodrug-ag-collaborators-explain-interplay-of-key-suspects-in-alzheimer%e2%80%99s-disease.html#comments</comments>
		<pubDate>Wed, 02 May 2012 00:00:20 +0000</pubDate>
		<dc:creator>akampion</dc:creator>
				<category><![CDATA[Company News]]></category>
		<category><![CDATA[Abeta peptide]]></category>
		<category><![CDATA[Alzheimer's disease]]></category>
		<category><![CDATA[Hans-Ulrich Demuth]]></category>
		<category><![CDATA[Journal of Neurochemistry]]></category>
		<category><![CDATA[Konrad Glund]]></category>
		<category><![CDATA[LMO]]></category>
		<category><![CDATA[Nature]]></category>
		<category><![CDATA[pGlu-Abeta]]></category>
		<category><![CDATA[prion diseases]]></category>
		<category><![CDATA[prions]]></category>
		<category><![CDATA[Probiodrug]]></category>
		<category><![CDATA[tau protein]]></category>
		<category><![CDATA[University of Virginia]]></category>

		<guid isPermaLink="false">http://akampioneer.com/?p=2684</guid>
		<description><![CDATA[Nature paper demonstrates that toxicity in AD is induced by pyroglutamate Abeta and is tau protein dependent Pyroglutamate Ab (“pyroglu Ab”) a predominant, highly toxic fraction of Aβ found in the brains of Alzheimer’s disease patients, triggers the formation of toxic oligomers exhibiting prion-like behavior and initiating neurotoxicity via a tau protein-dependent pathway, thereby explaining [...]]]></description>
		<wfw:commentRss>http://akampioneer.com/company-news/company-news-probiodrug-ag-collaborators-explain-interplay-of-key-suspects-in-alzheimer%e2%80%99s-disease.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Company News: InDex Pharmaceuticals Granted US Patent for Novel Treatment of Steroid-Resistant Inflammation</title>
		<link>http://akampioneer.com/company-news/company-news-index-pharmaceuticals-granted-us-patent-for-novel-treatment-of-steroid-resistant-inflammation.html</link>
		<comments>http://akampioneer.com/company-news/company-news-index-pharmaceuticals-granted-us-patent-for-novel-treatment-of-steroid-resistant-inflammation.html#comments</comments>
		<pubDate>Thu, 26 Apr 2012 08:19:49 +0000</pubDate>
		<dc:creator>akampion</dc:creator>
				<category><![CDATA[Company News]]></category>
		<category><![CDATA[asthma]]></category>
		<category><![CDATA[chronic obstructive pulmonary disease]]></category>
		<category><![CDATA[COLLECT study]]></category>
		<category><![CDATA[DNA-based immunomodulatory sequence (DIMS)]]></category>
		<category><![CDATA[emphysema]]></category>
		<category><![CDATA[InDex Pharmaceuticals]]></category>
		<category><![CDATA[inflammatory bowel disease]]></category>
		<category><![CDATA[Kappaproct®]]></category>
		<category><![CDATA[novel treatment option]]></category>
		<category><![CDATA[patent]]></category>
		<category><![CDATA[Phase III study]]></category>
		<category><![CDATA[psoriasis]]></category>
		<category><![CDATA[rheumatoid arthritis]]></category>
		<category><![CDATA[steroid-resistant inflammation]]></category>
		<category><![CDATA[toll-like receptor 9 (TLR9)]]></category>
		<category><![CDATA[UC]]></category>
		<category><![CDATA[ulcerative colitis]]></category>
		<category><![CDATA[US patent]]></category>

		<guid isPermaLink="false">http://akampioneer.com/?p=2662</guid>
		<description><![CDATA[InDex Pharmaceuticals today announced that it has been granted a patent by the United States Patent and Trademark Office. The patent provides additional protection for the use of Kappaproct® and additional DNA-based immunomodulatory sequences (DIMS) for the treatment of  steroid-resistant inflammatory diseases including inflammatory bowel disease, rheumatoid arthritis, psoriasis, asthma, emphysema and chronic obstructive pulmonary [...]]]></description>
		<wfw:commentRss>http://akampioneer.com/company-news/company-news-index-pharmaceuticals-granted-us-patent-for-novel-treatment-of-steroid-resistant-inflammation.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

